495 related articles for article (PubMed ID: 15077223)
21. [Combination of mycophenolate mofetil with cyclosporine A and methotrexate for the prophylaxes of acute graft versus host disease in allogeneic peripheral stem cell transplantation].
Wang J; Song X; Zhang W; Tong S; Hou J; Chen L; Lou J; Li H; Ding X; Min B
Zhonghua Yi Xue Za Zhi; 2002 Apr; 82(8):507-10. PubMed ID: 12133492
[TBL] [Abstract][Full Text] [Related]
22. Post-Transplant Cyclophosphamide and Tacrolimus-Mycophenolate Mofetil Combination Prevents Graft-versus-Host Disease in Allogeneic Peripheral Blood Hematopoietic Cell Transplantation from HLA-Matched Donors.
Carnevale-Schianca F; Caravelli D; Gallo S; Coha V; D'Ambrosio L; Vassallo E; Fizzotti M; Nesi F; Gioeni L; Berger M; Polo A; Gammaitoni L; Becco P; Giraudo L; Mangioni M; Sangiolo D; Grignani G; Rota-Scalabrini D; Sottile A; Fagioli F; Aglietta M
Biol Blood Marrow Transplant; 2017 Mar; 23(3):459-466. PubMed ID: 28039079
[TBL] [Abstract][Full Text] [Related]
23. Twice daily i.v. bolus tacrolimus infusion for GVHD prophylaxis in children undergoing stem cell transplantation.
Skeens M; Pai V; Garee A; Termuhlen AM; Bajwa RP; Gross TG; Soni S
Bone Marrow Transplant; 2012 Nov; 47(11):1415-8. PubMed ID: 22484323
[TBL] [Abstract][Full Text] [Related]
24. [Prophylaxis and treatment of chronic graft versus host disease].
Huang K; Li Y; Huang SL; Fang JP; Zhou DH; Chen C
Zhonghua Er Ke Za Zhi; 2005 Mar; 43(3):174-7. PubMed ID: 15833186
[TBL] [Abstract][Full Text] [Related]
25. Mycophenolate mofetil use after unrelated hematopoietic stem cell transplantation for prophylaxis and treatment of graft-vs.-host disease in adult patients in Japan.
Iida M; Fukuda T; Uchida N; Murata M; Aotsuka N; Minagawa K; Oohashi K; Fukushima K; Kondo T; Eto T; Miyamoto T; Morishima Y; Nagamura T; Atsuta Y; Suzuki R
Clin Transplant; 2014 Sep; 28(9):980-9. PubMed ID: 24943923
[TBL] [Abstract][Full Text] [Related]
26. Tacrolimus (FK506) and methotrexate as prophylaxis for acute graft-versus-host disease in pediatric allogeneic stem cell transplantation.
Yanik G; Levine JE; Ratanatharathorn V; Dunn R; Ferrara J; Hutchinson RJ
Bone Marrow Transplant; 2000 Jul; 26(2):161-7. PubMed ID: 10918426
[TBL] [Abstract][Full Text] [Related]
27. A randomized phase II trial comparing tacrolimus and mycophenolate mofetil to tacrolimus and methotrexate for acute graft-versus-host disease prophylaxis.
Perkins J; Field T; Kim J; Kharfan-Dabaja MA; Fernandez H; Ayala E; Perez L; Xu M; Alsina M; Ochoa L; Sullivan D; Janssen W; Anasetti C
Biol Blood Marrow Transplant; 2010 Jul; 16(7):937-47. PubMed ID: 20102746
[TBL] [Abstract][Full Text] [Related]
28. The outcome of unrelated donor bone marrow transplantation in patients with hematologic malignancies using tacrolimus (FK506) and low dose methotrexate for graft-versus-host disease prophylaxis.
Devine SM; Geller RB; Lin LB; Dix SP; Holland HK; Maurer D; O'Toole K; Keller J; Connaghan DG; Heffner LT; Hillyer CD; Rodey GE; Winton EF; Maher RM; Fitzsimmons WE; Wingard JR
Biol Blood Marrow Transplant; 1997 Apr; 3(1):25-33. PubMed ID: 9209738
[TBL] [Abstract][Full Text] [Related]
29. A phase I/II study of mycophenolate mofetil in combination with cyclosporine for prophylaxis of acute graft-versus-host disease after myeloablative conditioning and allogeneic hematopoietic cell transplantation.
Nash RA; Johnston L; Parker P; McCune JS; Storer B; Slattery JT; Furlong T; Anasetti C; Appelbaum FR; Lloid ME; Deeg HJ; Kiem HP; Martin PJ; Schubert MM; Witherspoon RP; Forman SJ; Blume KG; Storb R
Biol Blood Marrow Transplant; 2005 Jul; 11(7):495-505. PubMed ID: 15983549
[TBL] [Abstract][Full Text] [Related]
30. Risk Factors for Acute and Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation with Umbilical Cord Blood and Matched Sibling Donors.
Lazaryan A; Weisdorf DJ; DeFor T; Brunstein CG; MacMillan ML; Bejanyan N; Holtan S; Blazar BR; Wagner JE; Arora M
Biol Blood Marrow Transplant; 2016 Jan; 22(1):134-40. PubMed ID: 26365153
[TBL] [Abstract][Full Text] [Related]
31. Graft-versus-Host Disease Prophylaxis in Unrelated Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil.
Moiseev IS; Pirogova OV; Alyanski AL; Babenko EV; Gindina TL; Darskaya EI; Slesarchuk OA; Bondarenko SN; Afanasyev BV
Biol Blood Marrow Transplant; 2016 Jun; 22(6):1037-1042. PubMed ID: 26970381
[TBL] [Abstract][Full Text] [Related]
32. [Prophylaxis of acute graft-versus-host disease after allogeneic bone marrow transplantation by mycophenolate mofetil in a murine model].
Huang H; Zheng W; Lin M; Fu J; Zhang R
Zhonghua Xue Ye Xue Za Zhi; 2002 Apr; 23(4):191-3. PubMed ID: 12133455
[TBL] [Abstract][Full Text] [Related]
33. Tacrolimus and mycophenolate mofetil after nonmyeloablative matched-sibling donor allogeneic stem-cell transplantations conditioned with fludarabine and low-dose total body irradiation.
Nieto Y; Patton N; Hawkins T; Spearing R; Bearman SI; Jones RB; Shpall EJ; Rabinovitch R; Zeng C; Barón A; McSweeney PA
Biol Blood Marrow Transplant; 2006 Feb; 12(2):217-25. PubMed ID: 16443519
[TBL] [Abstract][Full Text] [Related]
34. Comparison of Tacrolimus and Sirolimus (Tac/Sir) versus Tacrolimus, Sirolimus, and mini-methotrexate (Tac/Sir/MTX) as acute graft-versus-host disease prophylaxis after reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation.
Ho VT; Aldridge J; Kim HT; Cutler C; Koreth J; Armand P; Antin JH; Soiffer RJ; Alyea EP
Biol Blood Marrow Transplant; 2009 Jul; 15(7):844-50. PubMed ID: 19539216
[TBL] [Abstract][Full Text] [Related]
35. Mycophenolate mofetil for the prophylaxis of acute GVHD in HLA-mismatched bone marrow transplant patients.
Basara N; Blau WI; Kiehl MG; Schmetzer B; Bischoff M; Kirsten D; Günzelmann S; Fauser AA
Clin Transplant; 2000 Apr; 14(2):121-6. PubMed ID: 10770416
[TBL] [Abstract][Full Text] [Related]
36. Mycophenolate mofetil and cyclosporine as graft-versus-host disease prophylaxis after allogeneic blood stem cell transplantation.
Bornhäuser M; Schuler U; Pörksen G; Naumann R; Geissler G; Thiede C; Schwerdtfeger R; Ehninger G; Thiede HM
Transplantation; 1999 Feb; 67(4):499-504. PubMed ID: 10071016
[TBL] [Abstract][Full Text] [Related]
37. [Quadruple therapy with CsA, MTX, MMF and ATG for preventing graft-versus-host disease in unrelated donor hematopoietic stem cell transplantation].
Liu QF; Sun J; Zhang Y; Xu D; Liu XL; Xu B; Meng FY; Zhou SY
Di Yi Jun Yi Da Xue Xue Bao; 2003 Nov; 23(11):1143-5. PubMed ID: 14625172
[TBL] [Abstract][Full Text] [Related]
38. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
Kröger N; Bornhäuser M; Ehninger G; Schwerdtfeger R; Biersack H; Sayer HG; Wandt H; Schäfer-Eckardt K; Beyer J; Kiehl M; Zander AR;
Ann Hematol; 2003 Jun; 82(6):336-42. PubMed ID: 12728337
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetics of intravenous mycophenolate mofetil in allogeneic hematopoietic stem cell-transplanted Japanese patients.
Kurata K; Yakushijin K; Okamura A; Yamamori M; Ichikawa H; Sakai R; Mizutani Y; Kakiuchi S; Miyata Y; Kitao A; Kawamoto S; Matsuoka H; Murayama T; Minami H
Cancer Chemother Pharmacol; 2018 May; 81(5):839-846. PubMed ID: 29511796
[TBL] [Abstract][Full Text] [Related]
40. Combination of low-dose mycophenolate mofetil with cyclosporine and methotrexate as GVHD prophylaxis in unrelated donor allogeneic stem cell transplantation.
Zhu X; Lai X; Luo Y; Shi J; Tan Y; Zheng W; He J; Xie W; Li L; Zhang J; Ye X; Lin M; Cai Z; Huang H
Leuk Res; 2013 Sep; 37(9):1046-51. PubMed ID: 23849987
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]